News | Radiation Oncology | December 12, 2019

Senate confirms Stephen Hahn, M.D., to serve as FDA Commissioner by Bipartisan Vote of 72-18

“Dr. Hahn can now get to work approving new life-saving drugs and devices, regulating tobacco and e-cigarettes, addressing the opioid crisis, ensuring pain patients can receive the medications they need and protecting our nation’s food supply.” – Senator Lamar Alexander

The American Society for Radiation Oncology (ASTRO) applauded the U.S. Senate for voting today to confirm radiation oncologist Stephen Hahn, M.D., FASTRO, as the next Commissioner of the Food and Drug Administration (FDA).

December 12, 2019 —The American Society for Radiation Oncology (ASTRO) applauded the U.S. Senate for voting today to confirm radiation oncologist Stephen Hahn, M.D., FASTRO, as the next Commissioner of the Food and Drug Administration (FDA).

“We applaud the U.S. Senate for confirming Dr. Stephen Hahn as the nation’s next Commissioner of the Food and Drug Administration. Dr. Hahn’s impressive background as a triple board-certified physician in medicine, medical oncology and radiation oncology coupled with his broad administrative experiences will allow him to ably lead the thousands of career professionals charged with ensuring U.S. consumer protection and public health,” said Theodore L. DeWeese, M.D., FASTRO, Chair of the ASTRO Board of Directors.  “Our support and respect for Dr. Hahn is based on his proven commitment to patients, science-based decision-making, and consumer health and safety. We look forward to his leadership as he steps into this critically important role as FDA Commissioner.”

Senate health committee Chairman Lamar Alexander (R-Tenn.) said that “Dr. Stephen Hahn’s experience as a practicing oncologist, a successful leader of the MD Anderson Cancer Center and work at the National Institutes of Health (NIH) make him the right leader for the FDA at this critical time.”

Hahn was confirmed by the Senate today by a bipartisan vote of 72-18 to serve as commissioner of the U.S. Food and Drug Administration (FDA).

“Dr. Hahn has extensive medical and research experience and is a proven leader in large health systems—all around, he is exactly the type of nominee we want to lead an agency as important as the FDA,” Alexander said. “The Senate health committee I chair received sixteen letters of support for Dr. Hahn representing more than 80 organizations on behalf of doctors, patients, researchers, and from his colleagues. Dr. Hahn has also received support from five previous FDA commissioners, who served under Presidents Trump, Obama and Bush.”

“Dr. Hahn can now get to work approving new life-saving drugs and devices, regulating tobacco and e-cigarettes, addressing the opioid crisis, ensuring pain patients can receive the medications they need and protecting our nation’s food supply.”

Alexander is chairman of the Senate health committee which has jurisdiction over confirmation of the FDA commissioner. Alexander chaired Hahn’s confirmation hearing on November 20, and the committee approved his nomination on December 3 by a bipartisan vote of 18-5. Alexander today voted in favor of Hahn’s nomination.

Hahn has previously served as the chief medical executive at the University of Texas MD Anderson Cancer Center in Houston. He is board certified in both medical oncology and radiation oncology, specializing over the course of his career on prostate, bladder, kidney, testicular, and lung cancers and sarcoma. 

Related content:

ASTRO Congratulates Stephen Hahn, M.D., for Securing Senate Committee Approval to lead FDA

ASTRO supports nomination of Stephen Hahn, M.D., FASTRO, to lead U.S. FDA

Related Content

Improvised PPE face mask worn by a radiology technologist during rounds atSen. Gerardo M. Roxas Memorial District Hospital in Iloilo City, Philippines. #COVID19 #Coronavirus #SARScov2

Improvised PPE face mask worn by a radiology technologist during rounds at Sen. Gerardo M. Roxas Memorial District Hospital in Iloilo City, Philippines.

Feature | Coronavirus (COVID-19) | April 02, 2020 | Dave Fornell, Editor
There has been an extraordinary demand for personal protective equipment (PPE) with the rapid spread of the novel ...
#COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2
News | Coronavirus (COVID-19) | March 31, 2020
March 31, 2020 — In a...
A new framework from an international team of experts aims to help protect patients and providers, and conserve protective equipment for frontline healthcare workers #COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2
News | Prostate Cancer | March 30, 2020
March 30, 2020 — In the wake of the COVID-19 pan
Women are more likely to be cured of cancer by radiotherapy but the side effects are worse.

Women are more likely to be cured of cancer by radiotherapy but the side effects are worse. Image by Mark Kostich

News | Radiation Therapy | March 30, 2020
March 30, 2020 — Women undergoing radiotherapy for
RSNA's open data repository will compile images and correlative data to create a comprehensive source for COVID-19 research and education efforts #COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2
News | Coronavirus (COVID-19) | March 30, 2020
March 30, 2020 — The medical imaging community around the world is uniting to help address the...
Phase III response to the COVID-19 public health emergency (PHE) CARES Act signed into law #CARESAct #COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2
Feature | Coronavirus (COVID-19) | March 28, 2020 | By Melinda Taschetta-Millane
On March 27, the House of Representatives approved a historic $2
AI vendor Infervision's InferRead CT Pneumonia software uses artificial intelligence-assisted diagnosis to improve the overall efficiency of the radiology department. It is being developed in China as a high sensitivity detection aid for novel coronavirus pneumonia (COVID-19). #COVID19 #coronavirus #SARScov2

AI vendor Infervision's InferRead CT Pneumonia software uses artificial intelligence-assisted diagnosis to improve the overall efficiency of the radiology department. It is being developed in China as a high sensitivity detection aid for novel coronavirus pneumonia (COVID-19).

Feature | Coronavirus (COVID-19) | March 27, 2020 | Jilian Liu, M.D., HIMSS Greater China
An older couple walked into the Hubei Provincial Hospital of Integrated Chinese and Western Medicine near their neigh
Novel scanners may open door for prognostic assessment in patients receiving cochlear implants

Iva Speck, MD, explains research showing that novel, fully digital, high-resolution positron emission tomography/computed tomography imaging of small brain stem nuclei can provide clinicians with valuable information concerning the auditory pathway in patients with hearing impairment. The research is featured in The Journal of Nuclear Medicine (read more at http://jnm.snmjournals.org/content/current). Video courtesy of Iva Speck, University Hospital Freiburg, Germany.

News | PET-CT | March 26, 2020
March 26, 2020 — Novel, fully digital, high-resolution...